(lp0
S'Curis May Make A Splash In Immune Checkpoint Inhibition Seeking Alpha - Jun 21, 2016 Curis, Inc. is a developmental biotech with one approved drug and an investigational agent in phase 2 clinical trials.'
p1
aS'Curis, Inc.  Could Reverse On Near Term Catalysts Insider Financial - Jul 22, 2016 Massachusetts based biotech Curis, Inc.  soared into the close of 2015, as data from its lead oncology candidate hinted at a revolution in cancer therapy.'
p2
aS'Stock Update : Curis, Inc. and Aurigene Extend Exclusivity Period ... Smarter Analyst - Jan 9, 2017 Curis, Inc.  announced that it has exercised its option to extend the exclusivity period with Aurigene under the collaboration, license and option agreement established in January, 2015.'
p3
aS'Curis to Present at the Oppenheimer &amp; Co. Inc. 27th Annual Healthcare Conference GlobeNewswire  - Mar 16, 2017 LEXINGTON, Mass., March 16, 2017  -- March 16, 2017 - Curis, Inc. , a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, today&nbsp;...'
p4
aS"Curis: One Swallow Doesn't Make A Summer Seeking Alpha - Nov 22, 2016 Curis Therapeutics   was incorporated on February 14, 2000 and trades on the Nasdaq Global Market. Headquartered in Lexington, Massachusetts, it is a clinical-stage biopharmaceutical company engaged in developing and&nbsp;..."
p5
aS'Company Update : Aurigene to Invest in Curis, Inc. at Premium ... Smarter Analyst - Sep 7, 2016 CRIS2 Curis, Inc. , a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of cancer, today announced that its collaborator, Aurigene Discovery Technologies&nbsp;...'
p6
aS'Curis to Present at the 2017 RBC Capital Markets Global Healthcare Conference GlobeNewswire  - Feb 17, 2017 LEXINGTON, Mass., Feb. 17, 2017  -- Curis, Inc. , a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, today announced that&nbsp;...'
p7
aS'Curis Inc Realized Volatility Hits An Escalated Level CML News - Feb 7, 2017 This is a proprietary realized volatility rating created by Capital Market Laboratories  based on a large number of data interactions for Curis Inc  . We examine the little used gem of daily stock volatility over a 20-day and 30 ...'
p8
aS'Checking the Levels for Curis Inc  Providence Standard - 9 hours ago Keeping an eye on moving averages for Curis Inc , the 50-day is 2.74, the 200-day is at 2.43, and the 7-day is 2.95. Moving averages have the ability to be used as a powerful indicator for technical stock analysis.'
p9
aS'Curis, Inc.  Upgraded by Zacks Investment Research to Hold Chaffey Breeze - Mar 15, 2017 Curis logo Curis, Inc.  was upgraded by Zacks Investment Research from a sell rating to a hold rating in a report issued on Tuesday.The Curis, Inc.  Releases Quarterly Earnings Results, Beats Expectations ... - Petro Global News 24Curis, Inc.  Upgraded to Hold at Zacks Investment Research - The Cerbat Gem'
p10
a.